Parsabiv for Secondary hyperparathyroidism in hemodialysis patients
Quick answer: Parsabiv is used for Secondary hyperparathyroidism in hemodialysis patients as part of a calcimimetic treatment regimen. Etelcalcetide allosterically activates calcium-sensing receptors on parathyroid cells to reduce PTH secretion The specific dosing for Secondary hyperparathyroidism in hemodialysis patients is determined by your prescriber based on individual factors.
Why is Parsabiv used for Secondary hyperparathyroidism in hemodialysis patients?
Parsabiv belongs to the Calcimimetic class. Etelcalcetide allosterically activates calcium-sensing receptors on parathyroid cells to reduce PTH secretion This action makes it useful for treating or managing Secondary hyperparathyroidism in hemodialysis patients in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Parsabiv is the right choice for a specific patient depends on the type and severity of Secondary hyperparathyroidism in hemodialysis patients, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Secondary hyperparathyroidism in hemodialysis patients
Common adult dosing range: 5 mg IV three times weekly at end of hemodialysis (range 2.5-15 mg). The actual dose for Secondary hyperparathyroidism in hemodialysis patients depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Parsabiv medicine page.
What to expect
Parsabiv treatment for Secondary hyperparathyroidism in hemodialysis patients typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Secondary hyperparathyroidism in hemodialysis patients
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Parsabiv is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Calcimimetic for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Parsabiv
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Parsabiv full prescribing information · All Calcimimetic alternatives
Frequently asked questions
How effective is Parsabiv for Secondary hyperparathyroidism in hemodialysis patients?
Effectiveness varies by individual response, dose, and severity. Parsabiv is one of several treatment options for Secondary hyperparathyroidism in hemodialysis patients, supported by clinical evidence within the calcimimetic class. Discuss expected response with your prescriber.
How long do I need to take Parsabiv for Secondary hyperparathyroidism in hemodialysis patients?
Treatment duration depends on the nature of Secondary hyperparathyroidism in hemodialysis patients — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Parsabiv when used for Secondary hyperparathyroidism in hemodialysis patients?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Parsabiv for Secondary hyperparathyroidism in hemodialysis patients?
Yes. Multiple medicines and non-drug options exist for Secondary hyperparathyroidism in hemodialysis patients. Alternatives within the calcimimetic class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.